

Manuel Romero-Gomez

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1674573/manuel-romero-gomez-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

402
papers

22,271
citations

64
h-index

142
g-index

600
ext. papers

29,392
ext. citations

4.9
avg, IF

6.72
L-index

#	Paper	IF	Citations
402	Performance of noninvasive tests of fibrosis among Asians, Hispanic and non-Hispanic Whites in the STELLAR trials.. <i>Clinical Gastroenterology and Hepatology</i> , 2022 ,	6.9	1
401	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.. <i>Journal of Hepatology</i> , 2022 ,	13.4	3
400	Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies.. <i>Journal of Clinical and Translational Hepatology</i> , 2022 , 10, 356-362	5.2	0
399	Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 ,	6.1	2
398	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. <i>JHEP Reports</i> , 2022 , 4, 100409	10.3	4
397	Long non-coding RNA H19 as biomarker for hepatocellular carcinoma.. <i>Liver International</i> , 2022 ,	7.9	2
396	Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation.. <i>Scientific Reports</i> , 2022 , 12, 3418	4.9	1
395	Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles.. <i>Hepatology</i> , 2022 ,	11.2	2
394	Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.. <i>Journal of Gastroenterology</i> , 2022 , 57, 357	6.9	1
393	Global multi-stakeholder endorsement of the MAFLD definition.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 ,	18.8	18
392	Correction to: A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure.. <i>American Journal of Gastroenterology</i> , 2022 , 117, 819	0.7	
391	Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review.. <i>Scientific Reports</i> , 2021 , 11, 24133	4.9	2
390	Impact of liver injury on the severity of COVID-19: a systematic review with meta-analysis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021 , 113, 125-135	0.9	4
389	Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases.. <i>Frontiers in Immunology</i> , 2021 , 12, 667354	8.4	1
388	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global NASH/NAFLD Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	4
387	Impact of COVID-19 on liver disease: From the experimental to the clinic perspective.. <i>World Journal of Virology</i> , 2021 , 10, 301-311	6.9	0
386	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37

385	Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2021 ,	11.2	7
384	The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. <i>EBioMedicine</i> , 2021 , 73, 103661	8.8	4
383	Overall clinical and economic impact of non-alcoholic fatty liver disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021 , 113, 396-403	0.9	
382	An Experimental DUAL Model of Advanced Liver Damage. <i>Hepatology Communications</i> , 2021 , 5, 1051-1068		2
381	Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. <i>Seminars in Liver Disease</i> , 2021 , 41, 191-205	7.3	4
380	Quality of Life and Coping in Nonalcoholic Fatty Liver Disease: Influence of Diabetes and Obesity. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	1
379	Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 1754-1768	4	2
378	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality 2021 ,		5
377	Development and Validation of a Clinical-Genetic Risk Score to Predict Hepatic Encephalopathy in Patients With Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1238-1247	0.7	2
376	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021 , 41, 1227-1242	7.9	20
375	Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD". <i>Journal of Hepatology</i> , 2021 , 74, 971-972	13.4	
374	Extra virgin olive oil improved body weight and insulin sensitivity in high fat diet-induced obese LDLr ^{-/-} .Leiden mice without attenuation of steatohepatitis. <i>Scientific Reports</i> , 2021 , 11, 8250	4.9	3
373	European MAFLD Preparedness IndexM Is Europe ready to meet the challenge of fatty liver disease?. <i>JHEP Reports</i> , 2021 , 3, 100234	10.3	13
372	Implementing Personalized Medicine in COVID-19 in Andalusia: An Opportunity to Transform the Healthcare System. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	4
371	Influence of Psychological Biomarkers on Therapeutic Adherence by Patients with Non-Alcoholic Fatty Liver Disease: A Moderated Mediation Model. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
370	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021 , 41, 2076-2086	7.9	5
369	Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. <i>Advanced Science</i> , 2021 , 8, 2004168	13.6	5
368	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2021 ,	19.2	31

367	A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. <i>Hepatology</i> , 2021 , 74, 133-147	11.2	20
366	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021 , 3, 100260.3	0.3	11
365	Management of NAFLD patients with advanced fibrosis. <i>Liver International</i> , 2021 , 41 Suppl 1, 95-104	7.9	3
364	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 717-729	24.2	16
363	Wilson's disease: Revisiting an old friend. <i>World Journal of Hepatology</i> , 2021 , 13, 634-649	3.4	6
362	A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1443-1451	3.4	0
361	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	9
360	Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 136-145.e6 ¹⁹	6.9	19
359	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 806-815.e5	6.9	21
358	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. <i>Hepatology</i> , 2021 , 73, 2238-2250	11.2	7
357	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. <i>Gastroenterology</i> , 2021 , 160, 193-205.e10	13.3	32
356	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2021 , 384, 1113-1124	59.2	244
355	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021 , 74, 1097-1108	13.4	41
354	Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation. <i>Clinical and Translational Medicine</i> , 2021 , 11, e275	5.7	
353	COVID-19 and the liver: the chicken or the egg dilemma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021 , 113, 555	0.9	
352	Looking for a new name for non-alcoholic fatty liver disease in Spanish: esteatosis hepática metabólica (EHmet). <i>Revista Espanola De Enfermedades Digestivas</i> , 2021 , 113, 161-163	0.9	2
351	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2021 ,	19.2	27
350	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. <i>Journal of Hepatology</i> , 2021 , 75, 86-97	13.4	18

349	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021 , 75, 342-350	13.4	10
348	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. <i>EBioMedicine</i> , 2021 , 70, 103521	8.8	5
347	A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. <i>American Journal of Gastroenterology</i> , 2021 ,	0.7	2
346	Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function. <i>Journal of Hepatology</i> , 2021 ,	13.4	1
345	Co-expression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease. <i>Journal of Hepatology</i> , 2021 , 75, 924-934	13.4	2
344	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021 , 75, 770-785	13.4	19
343	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021 , 75, 786-794	13.4	21
342	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	15
341	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. <i>EClinicalMedicine</i> , 2021 , 41, 101145	11.3	2
340	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2021 ,	13.4	7
339	Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients.. <i>World Journal of Gastroenterology</i> , 2021 , 27, 8343-8356	5.6	0
338	Clinical and sociodemographic determinants of disease progression in patients with nonalcoholic steatohepatitis in the United States.. <i>Medicine (United States)</i> , 2021 , 100, e28165	1.8	0
337	Circulating Tumor Cells Enumeration from the Portal Vein for Risk Stratification in Early Pancreatic Cancer Patients.. <i>Cancers</i> , 2021 , 13,	6.6	4
336	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020 , 383, 1522-1534	59.2	913
335	Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. <i>Liver International</i> , 2020 , 40, 2182-2193	7.9	6
334	Minimal Hepatic Encephalopathy. <i>Clinics in Liver Disease</i> , 2020 , 24, 209-218	4.6	5
333	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. <i>Journal of Hepatology</i> , 2020 , 73, 26-39	13.4	137
332	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020 , 73, 17-25	13.4	26

331	Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus. <i>American Journal of Gastroenterology</i> , 2020 , 115, 989-1002	0.7	25
330	The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management. <i>Liver International</i> , 2020 , 40 Suppl 1, 102-108	7.9	52
329	Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. <i>Cell Metabolism</i> , 2020 , 31, 605-622.e10	24.6	24
328	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020 , 158, 1999-2014.e1	13.3	748
327	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020 , 73, 202-209	13.4	764
326	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020 , 73, 1082-1091	13.4	52
325	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020 , 29, 235-245	1.4	9
324	Dietary Approach to NAFLD 2020 , 271-287		1
323	Morbid obesity and hepatitis C: treat as normal or are there additional issues to consider? 2020 , 59-65		
322	Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice. <i>Polish Archives of Internal Medicine</i> , 2020 , 130, 975-985	1.9	3
321	1449-P: The Enhanced Liver Fibrosis (ELF) Score Predicts Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH). <i>Diabetes</i> , 2020 , 69, 1449-P	0.9	
320	1850-P: High Prevalence of Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH): The Impact on Patient-Reported Outcomes (PROs). <i>Diabetes</i> , 2020 , 69, 1850-P	0.9	
319	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. <i>PLoS ONE</i> , 2020 , 15, e0243590	3.7	0
318	Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 778-783	0.9	
317	Coping strategies predicting quality of life in diabetic and obese NAFLD patients. <i>European Journal of Public Health</i> , 2020 , 30,	2.1	1
316	Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain. <i>Medicine (United States)</i> , 2020 , 99, e23506	1.8	2
315	qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020 , 71, 1953-1966	11.2	27
314	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020 , 174, 104694	10.8	20

313	Oral glutamine challenge is a marker of altered ammonia metabolism and predicts the risk of hepatic encephalopathy. <i>Liver International</i> , 2020 , 40, 921-930	7.9	2
312	Hepatitis C Virus Clearance by Direct-Acting Antiviral Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00203	4.2	9
311	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020 , 98, 106175	2.3	28
310	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020 , 73, 842-854	13.4	108
309	Psychological Biomarkers and Fibrosis: An Innovative Approach to Non-alcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020 , 7, 585425	4.9	7
308	Stratification of patients in NASH clinical trials: A pitfall for trial success. <i>JHEP Reports</i> , 2020 , 2, 100148	10.3	9
307	Negative predictive value of the repeated absence of gluten immunogenic peptides in the urine of treated celiac patients in predicting mucosal healing: new proposals for follow-up in celiac disease. <i>American Journal of Clinical Nutrition</i> , 2020 , 112, 1240-1251	7	32
306	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. <i>JHEP Reports</i> , 2020 , 2, 100143	10.3	20
305	Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. <i>Hepatology Communications</i> , 2020 , 4, 1637-1650	6	12
304	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , 2020 , 72, 14-24	13.4	75
303	Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 216-225.e5	6.9	46
302	Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2819-2821	6.9	11
301	Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. <i>Transplantation</i> , 2019 , 103, 28-38	1.8	16
300	Water-soluble extracts from edible mushrooms (<i>Agaricus bisporus</i>) as inhibitors of hepatitis C viral replication. <i>Food and Function</i> , 2019 , 10, 3758-3767	6.1	10
299	PS-022-Optimal timing of endoscopy is associated with lower 42-day mortality in variceal bleeding. <i>Journal of Hepatology</i> , 2019 , 70, e16-e17	13.4	2
298	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2552-2560.e10	6.9	33
297	PS-200-The combination of HEPAmet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD. <i>Journal of Hepatology</i> , 2019 , 70, e133-e134	13.4	3
296	Cardiotrophin-1 is an anti-inflammatory cytokine and promotes IL-4-induced M2 macrophage polarization. <i>FASEB Journal</i> , 2019 , 33, 7578-7587	0.9	6

295	Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2085-2092.e1	6.9	41
294	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF- β dependent mechanisms. <i>Scientific Reports</i> , 2019 , 9, 1439	4.9	6
293	Use of Steatotic Grafts in Liver Transplantation: Current Status. <i>Liver Transplantation</i> , 2019 , 25, 771-786	4.5	12
292	Preemptive-TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , 2019 , 69, 282-293	11.2	73
291	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 748-755.e3	6.9	311
290	Does the Antitumor Necrosis Factor- β Therapy Decrease the Vertebral Fractures Occurrence in Inflammatory Bowel Disease?. <i>Journal of Clinical Densitometry</i> , 2019 , 22, 195-202	3.5	11
289	Relationship Between Self-Perceived Health, Vitality, and Posttraumatic Growth in Liver Transplant Recipients. <i>Frontiers in Psychology</i> , 2019 , 10, 1367	3.4	1
288	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019 , 70, 1521-1530	11.2	113
287	Usefulness of bioelectrical impedance analysis for monitoring patients with refractory ascites. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 223-227	0.9	2
286	Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 264-269	0.9	8
285	Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 301-307	0.9	2
284	Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 270-274	0.9	2
283	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 862-873	0.9	4
282	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 579-592	0.9	13
281	Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH. <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 657-676	0.9	3
280	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1625-1633.e1	6.9	56
279	P: 1 Genetic Fingerprint of Hepatic Encephalopathy Risk in Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2019 , 114, S1-S1	0.7	
278	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 2184-2196	4.0	425

277	Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019 , 42, 657-676	0.1	1
276	A Pilot Study of Serum Sphingomyelin Dynamics in Subjects with Severe Obesity and Non-alcoholic Steatohepatitis after Sleeve Gastrectomy. <i>Obesity Surgery</i> , 2019 , 29, 983-989	3.7	3
275	A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'MTR. <i>Journal of Hepatology</i> , 2019 , 70, 494-500	13.4	46
274	Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 55-64	3.4	16
273	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 328-349	0.9	30
272	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1495-1502	6.9	55
271	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. <i>Journal of Hepatology</i> , 2018 , 68, 940-948	13.4	12
270	Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections: A real-life experience. <i>International Journal of Infectious Diseases</i> , 2018 , 67, 114-117	10.5	19
269	Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. <i>Therapeutic Advances in Gastroenterology</i> , 2018 , 11, 1756283X17743419	4.7	8
268	Diagnostic accuracy of SCCA and SCCA-IgM for hepatocellular carcinoma: A meta-analysis. <i>Liver International</i> , 2018 , 38, 1820-1831	7.9	11
267	New therapeutic perspectives in non-alcoholic steatohepatitis. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 128-142	0.1	
266	New therapeutic perspectives in non-alcoholic steatohepatitis. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 128-142	0.9	8
265	DRESS cases included in the Spanish and Latin-American DILI registries: clinical phenotype and outcome. <i>Journal of Hepatology</i> , 2018 , 68, S601	13.4	3
264	miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2018 , 69, 1335-1348	13.4	73
263	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , 2018 , 69, 896-904	13.4	550
262	Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. <i>PLoS ONE</i> , 2018 , 13, e0191805	3.7	18
261	Metformin modifies glutamine metabolism in an in vitro and in vivo model of hepatic encephalopathy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018 , 110, 427-433	0.9	3
260	Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 718-725	4	24

259	High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 292-294	6.9	11
258	Natural Extracts Abolished Lipid Accumulation in Cells Harboring non-favourable PNPLA3 genotype. <i>Annals of Hepatology</i> , 2018 , 17, 242-249	3.1	9
257	Peer-to-Peer Sessions in Primary Care to Improve the Hepatitis B Detection Rate in Seville, Spain. <i>Annals of Hepatology</i> , 2018 , 17, 864-870	3.1	0
256	Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018 , 110, 641-649	0.9	2
255	Modulation of faecal metagenome in Crohn's disease: Role of microRNAs as biomarkers. <i>World Journal of Gastroenterology</i> , 2018 , 24, 5223-5233	5.6	19
254	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1260-1270	6.1	43
253	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 328-349	0.1	1
252	Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. <i>Hepatology Communications</i> , 2018 , 2, 807-820	6	64
251	Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. <i>Gastroenterology</i> , 2018 , 155, 443-457.e173	17.3	308
250	Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2017 , 152, 1449-1461.e7	13.3	139
249	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. <i>Hepatology</i> , 2017 , 65, 1810-1822	11.2	64
248	IFN- β , not IFN- α , likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017 , 49, 795-800	36.3	72
247	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017 , 37, 1823-1832	7.9	8
246	Long-term follow-up of patients with chronic hepatitis C treated with Interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response. <i>European Journal of Gastroenterology and Hepatology</i> , 2017 , 29, 792-799	2.2	4
245	Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 468-475	6.1	26
244	Treatment of NAFLD with diet, physical activity and exercise. <i>Journal of Hepatology</i> , 2017 , 67, 829-846	13.4	492
243	Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 1305-1312	4	35
242	TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2017 , 153, 1448-1449	13.3	6

241	Evolution of the incidence of inflammatory bowel disease in Southern Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017 , 109, 757-760	0.9	5
240	Hepatitis B and NAFLD: Lives Crossed. <i>Annals of Hepatology</i> , 2017 , 16, 185-187	3.1	4
239	Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma. <i>Annals of Hepatology</i> , 2017 , 16, 198-206	3.1	12
238	Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. <i>European Journal of Gastroenterology and Hepatology</i> , 2017 , 29, 1290-1295	2.2	34
237	An extra virgin olive oil rich diet intervention ameliorates the nonalcoholic steatohepatitis induced by a high-fat "Western-type" diet in mice. <i>Molecular Nutrition and Food Research</i> , 2017 , 61, 1600549	5.9	33
236	Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 332-344	6.1	32
235	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017 , 112, 740-751	0.7	273
234	Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. <i>Liver International</i> , 2017 , 37, 212-223	7.9	17
233	Endoscopic ultrasound-guided placement of plastic pigtail stents for the drainage of refractory malignant ascites. <i>Endoscopy International Open</i> , 2017 , 5, E1096-E1099	3	3
232	A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017 , 109, 552-558	0.9	14
231	Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. <i>World Journal of Hepatology</i> , 2017 , 9, 697-703	3.4	8
230	Reply to contribution on the topic of hypovitaminosis D in chronic hepatitis C. <i>Annals of Hepatology</i> , 2016 , 15, 139-40	3.1	0
229	Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 877-89	6.1	54
228	Pharmacogenetics of ribavirin-induced anemia in hepatitis C. <i>Pharmacogenomics</i> , 2016 , 17, 1587-94	2.6	7
227	Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. <i>Psychopharmacology</i> , 2016 , 233, 3947-3952	4.7	26
226	Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry. <i>Rheumatology International</i> , 2016 , 36, 1627-1632	3.6	5
225	MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. <i>Nature Communications</i> , 2016 , 7, 12757	17.4	73
224	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016 , 6, 31421	4.9	22

223	Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50, 779-89	3	20
222	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016 , 64, 34-46	11.2	65
221	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016 , 64, 390-398	13.4	55
220	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor- α , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016 , 150, 1147-1159.e5	13.3	629
219	Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis. <i>Digestive and Liver Disease</i> , 2016 , 48, 283-90	3.3	25
218	Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry. <i>Rheumatology International</i> , 2016 , 36, 231-41	3.6	9
217	A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin. <i>PLoS ONE</i> , 2016 , 11, e0150569	3.7	4
216	Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. <i>World Journal of Gastroenterology</i> , 2016 , 22, 5285-92	5.6	8
215	Low phase angle is associated with the development of hepatic encephalopathy in patients with cirrhosis. <i>World Journal of Gastroenterology</i> , 2016 , 22, 10064-10070	5.6	15
214	Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish Patients. <i>Frontiers in Pharmacology</i> , 2016 , 7, 280	5.6	
213	Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1611-8	4	17
212	Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. <i>Hepatology</i> , 2016 , 63, 1875-87	11.2	41
211	Reply. <i>Hepatology</i> , 2016 , 64, 2266-2267	11.2	
210	Effect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host Targets. <i>Scientific Reports</i> , 2016 , 6, 31777	4.9	52
209	Treatment of Hepatitis C Virus in Patients with Advanced Cirrhosis: Always Justified? Analysis of the Hepa-C Registry. <i>Journal of Hepatology</i> , 2016 , 64, S133	13.4	8
208	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. <i>Journal of Hepatology</i> , 2016 , 65, 532-42	13.4	82
207	Case Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis. <i>Seminars in Liver Disease</i> , 2016 , 36, 181-6	7.3	2
206	PLPNA3 Status in Nash is Associated with Increased Histological Severity at Baseline but Not with Response to Therapy in the Golden-505 Elafibranor Trial. <i>Journal of Hepatology</i> , 2016 , 64, S147	13.4	2

205	Variations in the Promoter Region of the Glutaminase Gene and the Development of Hepatic Encephalopathy in Patients with Cirrhosis. <i>Journal of Hepatology</i> , 2016 , 64, S257	13.4	2
204	Fecal Gluten Peptides Reveal Limitations of Serological Tests and Food Questionnaires for Monitoring Gluten-Free Diet in Celiac Disease Patients. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1456-1465	0.7	107
203	Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. <i>Clinical Microbiology and Infection</i> , 2016 , 22, 839-845	9.5	25
202	Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 112-8	4	9
201	Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. <i>Journal of Clinical Virology</i> , 2015 , 68, 56-60	14.5	9
200	The value of serum aspartate aminotransferase and gamma-glutamyl transpeptidase as biomarkers in hepatotoxicity. <i>Liver International</i> , 2015 , 35, 2474-82	7.9	31
199	Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2015 , 149, 367-78.e5; quiz e14-5	13.3	1010
198	Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection. <i>Genes and Immunity</i> , 2015 , 16, 297-300	4.4	8
197	Interferon- λ 12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. <i>Nature Communications</i> , 2015 , 6, 6422	17.4	127
196	Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. <i>European Journal of Gastroenterology and Hepatology</i> , 2015 , 27, 46-54	2.2	4
195	Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 1301-8	4	4
194	Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis. <i>Gastroenterology</i> , 2015 , 149, 1483-9	13.3	80
193	Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3. <i>Gastroenterology Clinics of North America</i> , 2015 , 44, 845-57	4.4	13
192	High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 219-26	9.7	64
191	Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. <i>Liver International</i> , 2015 , 35, 90-100	7.9	12
190	Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015 , 62, 437-47	13.4	140
189	Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 469-80	3.4	6
188	Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 829-44	6.1	28

187	99.7% Sustained Virologic Response Rate in 369 HCV Genotype 1b-Infected Patients Treated With Label-Recommended Regimen of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin. <i>American Journal of Gastroenterology</i> , 2015 , 110, S850-S851	0.7	4
186	Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin. <i>World Journal of Hepatology</i> , 2015 , 7, 1105-11	3.4	25
185	Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 9163-74	5.6	10
184	Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study. <i>PLoS ONE</i> , 2015 , 10, e0122613	3.7	1
183	Assessing cardiovascular risk in hepatitis C: An unmet need. <i>World Journal of Hepatology</i> , 2015 , 7, 2214-9	3.4	21
182	Hypovitaminosis D and its relation to demographic and laboratory data among hepatitis C patients. <i>Annals of Hepatology</i> , 2015 , 14, 457-463	3.1	11
181	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , 2015 , 14, 477-486	3.1	1
180	Reply: To PMID 25865049. <i>Gastroenterology</i> , 2015 , 149, 1988-9	13.3	2
179	Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies. <i>World Journal of Gastroenterology</i> , 2015 , 21, 10776-82	5.6	14
178	Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field. <i>World Journal of Hepatology</i> , 2015 , 7, 2497-502	3.4	32
177	The Oral Glutamine Challenge in Liver Cirrhosis 2015 , 229-236		
176	Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015 , 107, 10-6	0.9	52
175	Hypovitaminosis D and its relation to demographic and laboratory data among hepatitis C patients. <i>Annals of Hepatology</i> , 2015 , 14, 457-63	3.1	4
174	Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats. <i>Journal of Hepatology</i> , 2014 , 60, 545-53	13.4	26
173	Serum selenium levels and oxidative balance as differential markers in hepatic damage caused by alcohol. <i>Life Sciences</i> , 2014 , 94, 158-63	6.8	22
172	IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. <i>Journal of Hepatology</i> , 2014 , 61, 235-41	13.4	33
171	Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. <i>New England Journal of Medicine</i> , 2014 , 370, 1889-98	59.2	1402
170	Use of HyMlaw and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. <i>Gastroenterology</i> , 2014 , 147, 109-118.e5	13.3	186

169	ABT-450/sofosbuvir and dasabuvir with or without ribavirin for HCV. <i>New England Journal of Medicine</i> , 2014 , 370, 1983-92	59.2	594
168	Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease. <i>European Journal of Clinical Investigation</i> , 2014 , 44, 65-73	4.6	31
167	Cost-Effectiveness Analysis of Eltrombopag As Support Treatment In Chronic Hcv Infected Patients With Thrombocytopenia To Enable Interferon-Based Regimens. <i>Value in Health</i> , 2014 , 17, A532	3.3	
166	Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under "Real-Life" Conditions. <i>Value in Health</i> , 2014 , 17, A367	3.3	
165	Hepatitis C virus infection alters lipid metabolism depending on IL28B polymorphism and viral genotype and modulates gene expression in vivo and in vitro. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 19-24	3.4	19
164	Stanozolol-induced bland cholestasis. <i>Gastroenterologia Y Hepatologia</i> , 2014 , 37, 71-2	0.9	8
163	P219 FINE MAPPING OF THE BUTYROPHILIN GENOMICS REGION: ROLE IN HEPATITIS C VIRUS INFECTION (HCV). <i>Journal of Hepatology</i> , 2014 , 60, S139	13.4	2
162	Reply to: "Renal impairment and anemia during triple therapy". <i>Journal of Hepatology</i> , 2014 , 60, 1100-1	13.4	1
161	P1121 EARLY STOPPING RULES FOR FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: EXPLORATORY STUDY OF POOLED DATA FROM PHASE III TRIALS. <i>Journal of Hepatology</i> , 2014 , 60, S452-S453	13.4	2
160	Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection. <i>Gastroenterology</i> , 2014 , 147, 119-131.e3	13.3	26
159	Review article: HCV genotype 3 The new treatment challenge. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 686-98	6.1	93
158	Sofosbuvir and ribavirin in HCV genotypes 2 and 3. <i>New England Journal of Medicine</i> , 2014 , 370, 1993-2001	59.2	671
157	THDP17 decreases ammonia production through glutaminase inhibition. A new drug for hepatic encephalopathy therapy. <i>PLoS ONE</i> , 2014 , 9, e109787	3.7	11
156	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , 2014 , 13, 356-363	3.1	15
155	Irisin, a link among fatty liver disease, physical inactivity and insulin resistance. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 23163-78	6.3	47
154	Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study. <i>Gastroenterologia Y Hepatologia</i> , 2014 , 37, 1-8	0.9	2
153	Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 291-5	4	23
152	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , 2014 , 13, 356-63	3.1	12

151	Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry. <i>Revista Espanola De Enfermedades Digestivas</i> , 2014 , 106, 246-54	0.9	39
150	Role of diabetes mellitus on hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2013 , 28, 277-9	3.9	25
149	Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. <i>Journal of Hepatology</i> , 2013 , 58, 792-800	13.4	88
148	Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations. <i>Journal of Hepatology</i> , 2013 , 59, 1323-30	13.4	29
147	EUS-guided coil versus cyanoacrylate therapy for the treatment of gastric varices: a multicenter study (with videos). <i>Gastrointestinal Endoscopy</i> , 2013 , 78, 711-21	5.2	161
146	Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain. <i>Gastroenterología Y Hepatología</i> , 2013 , 36, 555-64	0.9	1
145	104 A CANDIDATE-GENE APPROACH TO VALIDATION OF GENETIC MODIFIER ASSOCIATIONS USING A LARGE COHORT WITH HISTOLOGICALLY CHARACTERISED NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2013 , 58, S46	13.4	6
144	Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 74-80	6.1	16
143	Association between vitamin D and hepatitis C virus infection: a meta-analysis. <i>World Journal of Gastroenterology</i> , 2013 , 19, 5917-24	5.6	69
142	Meta-analysis: pegylated interferon α 2a achieves higher early virological responses than α 2b in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 1065-73	6.1	6
141	Community-acquired pneumonia during the first post-pandemic influenza season: a prospective, multicentre cohort study. <i>Journal of Infection</i> , 2013 , 67, 185-93	18.9	21
140	PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. <i>Hepatology</i> , 2013 , 58, 524-37	11.2	38
139	Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. <i>World Journal of Gastroenterology</i> , 2013 , 19, 7327-40	5.6	77
138	HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. <i>PLoS ONE</i> , 2013 , 8, e68111	3.7	66
137	Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables. <i>Annals of Hepatology</i> , 2013 , 12, 420-430	3.1	18
136	Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012 , 27, 1705-10	4	
135	1154 PEGINTERFERON ALPHA-2A ACHIEVES HIGHER EARLY VIROLOGICAL RESPONSES (RVR AND CEVR) THAN PEGINTERFERON ALPHA-2B IN CHRONIC HEPATITIS C: META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS (RCT). <i>Journal of Hepatology</i> , 2012 , 56, S456	13.4	2
134	1403 SIGNIFICANT IMPROVEMENT OF COMPLETE EVR IN HCVAC PHASE II CLINICAL TRIAL WHEN ADDING TG4040 THERAPEUTIC VACCINE TO PEGIFN α 2A AND RIBAVIRIN. <i>Journal of Hepatology</i> , 2012 , 56, S552	13.4	5

133	Knowledge discovery of customer satisfaction and dissatisfaction using ontology-based text analysis of critical incident dialogues 2012 ,		1
132	Unsedated colonoscopy: an option for some but not for all. <i>Gastrointestinal Endoscopy</i> , 2012 , 75, 392-8	5.2	37
131	Re: Unsedated colonoscopy: an option for some but not for all. <i>Gastrointestinal Endoscopy</i> , 2012 , 76, 699; author reply 699	5.2	1
130	Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. <i>PLoS ONE</i> , 2012 , 7, e49279	3.7	42
129	The hepatitis C virus modulates insulin signaling pathway in vitro promoting insulin resistance. <i>PLoS ONE</i> , 2012 , 7, e47904	3.7	17
128	Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. <i>Journal of Proteome Research</i> , 2012 , 11, 2521-32	5.6	137
127	Immunosuppressed patients with pandemic influenza A 2009 (H1N1) virus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012 , 31, 547-56	5.3	26
126	HAVCR1 gene haplotypes and infection by different viral hepatitis C virus genotypes. <i>Vaccine Journal</i> , 2012 , 19, 223-7		8
125	Insulin resistance impairs viral dynamics independently of ethnicity or genotypes. <i>Journal of Clinical Gastroenterology</i> , 2012 , 46, 228-34	3	9
124	Efficacy and safety of entecavir in clinical practice in treatment-naïve Caucasian chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2012 , 24, 535-42	2.2	21
123	Entry of hepatitis C virus into the cell: a therapeutic target. <i>World Journal of Gastroenterology</i> , 2012 , 18, 4481-5	5.6	8
122	Relationship between H. pylori and hepatitis A virus infection. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012 , 104, 220-1	0.9	2
121	Invasive pulmonary aspergillosis in a young man with Crohn's disease. <i>Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation</i> , 2012 , 33, 294-5		
120	Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. <i>Gastroenterology</i> , 2011 , 140, 469-77	13.3	58
119	Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. <i>Gastroenterology</i> , 2011 , 141, 338-47	13.3	359
118	Cutaneous lymphoma in a patient with ulcerative colitis after immunosuppressive therapy. <i>Journal of Crohn's and Colitis</i> , 2011 , 5, 608-11	1.5	8
117	Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1246-54	0.7	28
116	4 ONCE DAILY ALISPORIVIR (DEB025) PLUS PEGIFNALFA2A/RIBAVIRIN RESULTS IN SUPERIOR SUSTAINED VIROLOGIC RESPONSE (SVR24) IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT NAIVE PATIENTS. <i>Journal of Hepatology</i> , 2011 , 54, S2	13.4	34

115	505 IBUPROFEN-ASSOCIATED HEPATOTOXICITY: ANALYSIS OF A CASE SERIES INCLUDED IN THE SPANISH DILI REGISTRY. <i>Journal of Hepatology</i> , 2011 , 54, S206	13.4	2
114	Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept. <i>Revista Espanola De Enfermedades Digestivas</i> , 2011 , 103, 619-25	0.9	3
113	The role of insulin resistance in HIV/hepatitis C virus-coinfected patients. <i>Current Opinion in HIV and AIDS</i> , 2011 , 6, 553-8	4.2	6
112	Meta-analysis: insulin resistance and sustained virological response in hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 297-305	6.1	82
111	Use of HOMA-IR in hepatitis C. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 675-84	3.4	31
110	Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. <i>Liver International</i> , 2011 , 31, 443-60	7.9	44
109	Brain biomolecules oxidation in portacaval-shunted rats. <i>Liver International</i> , 2011 , 31, 964-9	7.9	11
108	Perspectives from Spanish infectious diseases professionals on 2009 A (H1N1) influenza: the third half. <i>Clinical Microbiology and Infection</i> , 2011 , 17, 845-50	9.5	6
107	Hepatitis C Virus and Statins: Is There a Role?. <i>Current Hepatitis Reports</i> , 2011 , 10, 162-167		
106	Endoscopic closure of a rectovaginal fistula combining N-2-butyl-cyanoacrylate (Histoacryl) and Resolution clips. <i>Endoscopy</i> , 2011 , 43 Suppl 2 UCTN, E133-4	3.4	6
105	Experimental models for hepatic encephalopathy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2011 , 103, 536-41	0.9	6
104	Power Doppler ultrasonography assessment of entheses in spondyloarthropathies: response to therapy of enthesal abnormalities. <i>Journal of Rheumatology</i> , 2010 , 37, 2110-7	4.1	97
103	Propranolol-induced angioedema in a patient with chronic hepatitis C virus infection. <i>American Journal of Health-System Pharmacy</i> , 2010 , 67, 1182-4	2.2	4
102	Campylobacter fetus peritonitis and bacteremia in a patient undergoing continuous ambulatory peritoneal dialysis. <i>Journal of Clinical Microbiology</i> , 2010 , 48, 336-7	9.7	17
101	Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management. <i>Digestive Diseases</i> , 2010 , 28, 285-93	3.2	6
100	Serum metabolic signature of minimal hepatic encephalopathy by (1)H-nuclear magnetic resonance. <i>Journal of Proteome Research</i> , 2010 , 9, 5180-7	5.6	46
99	Pharmacotherapy of hepatic encephalopathy in cirrhosis. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 1317-27	4	20
98	513 DOUBLE-BLINDED CROSSOVER TRIAL ANALYZING THE USEFULNESS OF RIFAXIMIN IN THE TREATMENT OF MINIMAL HEPATIC ENCEPHALOPATHY (MHE): AN INTERIM ANALYSIS. <i>Journal of Hepatology</i> , 2010 , 52, S206-S207	13.4	2

97	Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. <i>American Journal of Gastroenterology</i> , 2010 , 105, 2164-72; quiz 2173	0.7	53
96	1137 THE HLA CLASS I B*1801 ALLELE INFLUENCES HEPATOCELLULAR EXPRESSION OF AMOXICILLIN-CLAVULANATE LIVER DAMAGE AND OUTCOME IN SPANISH PATIENTS. <i>Journal of Hepatology</i> , 2010 , 52, S439	13.4	3
95	Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. <i>Annals of Internal Medicine</i> , 2010 , 153, 281-8	8	53
94	Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. <i>Hepatology</i> , 2010 , 52, 33-7	11.2	166
93	Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2010 , 52, 303-12	11.2	85
92	Reply:. <i>Hepatology</i> , 2010 , 52, 1861-1862	11.2	1
91	Cronkhite-Canada syndrome: a new case report of this enigmatic and infrequent disease. <i>Revista Espanola De Enfermedades Digestivas</i> , 2010 , 102, 208-15	0.9	
90	Steatosis and insulin resistance in hepatitis C: a way out for the virus?. <i>World Journal of Gastroenterology</i> , 2009 , 15, 5014-9	5.6	48
89	Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. <i>Hepatology</i> , 2009 , 49, 2001-9	11.2	221
88	Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. <i>Hepatology</i> , 2009 , 50, 1702-8	11.2	110
87	Reply:. <i>Hepatology</i> , 2009 , 50, 2055-2055	11.2	
86	Gut ammonia production and its modulation. <i>Metabolic Brain Disease</i> , 2009 , 24, 147-57	3.9	62
85	Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. <i>Liver International</i> , 2009 , 29, 629-35	7.9	160
84	Results of a survey about specific inflammatory bowel disease units in Andalusia. <i>Revista Espanola De Enfermedades Digestivas</i> , 2009 , 101, 187-94	0.9	4
83	Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate <i>Helicobacter pylori</i> . <i>Revista Espanola De Enfermedades Digestivas</i> , 2009 , 101, 395-8, 399-402	0.9	12
82	Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 27, 780-9	6.1	112
81	Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. <i>Journal of Hepatology</i> , 2008 , 48, 721-7	13.4	158
80	Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. <i>Journal of Hepatology</i> , 2008 , 49, 107-14	13.4	63

79	Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin. <i>Journal of Clinical Virology</i> , 2008 , 41, 264-9	14.5	15
78	1001 INTERIM ANALYSIS FROM TRIC-1 A STUDY OF METFORMIN WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAIVE GENOTYPE 1 CHRONIC HEPATITIS C WITH INSULIN RESISTANCE. <i>Journal of Hepatology</i> , 2008 , 48, S375	13.4	4
77	PTPN22 C1858T polymorphism and the outcome of hepatitis C virus infection. <i>Viral Immunology</i> , 2008 , 21, 491-4	1.7	5
76	Pathogenesis and natural course of hepatic steatosis and insulin resistance in patients with hepatitis C. <i>Current Hepatitis Reports</i> , 2008 , 7, 113-119		
75	Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. <i>Hepatology</i> , 2008 , 47, 810-6	11.2	39
74	Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2008 , 48, 588-96	11.2	162
73	¿Cuáles el tratamiento estándar de la encefalopatía hepática? Lecciones de los ensayos clínicos en el tratamiento de la encefalopatía hepática. <i>Gastroenterología Y Hepatología Continuada</i> , 2007 , 6, 192-193		1
72	Expression of bcl-2 in ductular proliferation is related to periportal hepatic stellate cell activation and fibrosis progression in patients with autoimmune cholestasis. <i>Digestive and Liver Disease</i> , 2007 , 39, 262-6	3.3	13
71	Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. <i>Hepatology</i> , 2007 , 45, 879-85	11.2	233
70	Treatment of chronic hepatitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 25, 899-906	6.1	9
69	Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 1131-8	6.1	28
68	Pneumatic perforation of the cecum during diagnostic sigmoidoscopy. <i>Endoscopy</i> , 2007 , 39 Suppl 1, E183-4	3.4	3
67	Critical flicker frequency: it is time to break down barriers surrounding minimal hepatic encephalopathy. <i>Journal of Hepatology</i> , 2007 , 47, 10-1	13.4	17
66	[638] INFLUENCE OF INSULIN RESISTANCE AND RIBAVIRIN DOSAGE IN VIRAL DYNAMICS OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 TREATED WITH PEGINTERFERON AND RIBAVIRIN. <i>Journal of Hepatology</i> , 2007 , 46, S241	13.4	2
65	CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population. <i>World Journal of Gastroenterology</i> , 2007 , 13, 2187-92	5.6	4
64	Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2006 , 43, 72-80	11.2	41
63	Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. <i>Hepatology</i> , 2006 , 44, 850-6	11.2	121
62	Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. <i>Hepatology</i> , 2006 , 44, 1581-8	11.2	223

61	Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfecting patients with decompensated cirrhosis. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 1236-41	1.6	17
60	Different approaches to therapy of esophageal granular cell tumor (Abrikossoff tumor). <i>Scandinavian Journal of Gastroenterology</i> , 2006 , 41, 993-4	2.4	1
59	Interorgan ammonia, glutamate, and glutamine trafficking in pigs with acute liver failure. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 291, G373-81	5.1	30
58	230 Usefulness of the measurement of critical flicker frequency in the diagnosis of minimal hepatic encephalopathy (MHE). <i>Journal of Hepatology</i> , 2006 , 44, S93	13.4	2
57	548 Sustained response in chronic hepatitis C reduces the risk to develop impaired fasting glucose and/or diabetes mellitus type 2. <i>Journal of Hepatology</i> , 2006 , 44, S204	13.4	3
56	566 Pharmacokinetics and pharmacodynamics of induction doses of peginterferon alpha-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) in HCV genotype 1 patients who failed to respond to interferon/ribavirin. <i>Journal of Hepatology</i> , 2006 , 44, S210-S211	13.4	2
55	Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. <i>Gastroenterology</i> , 2006 , 131, 451-60	13.3	311
54	Tratamiento de la hepatitis crónica C por genotipos 2 y 3: revisión sistemática. <i>Gastroenterología Y Hepatología</i> , 2006 , 29, 139-145	0.9	
53	Acute hepatitis due to <i>Mycoplasma pneumoniae</i> infection without lung involvement in adult patients. <i>Journal of Hepatology</i> , 2006 , 44, 827-8	13.4	22
52	Insulin resistance and hepatitis C. <i>World Journal of Gastroenterology</i> , 2006 , 12, 7075-80	5.6	120
51	Phosphate-activated glutaminase activity is enhanced in brain, intestine and kidneys of rats following portacaval anastomosis. <i>World Journal of Gastroenterology</i> , 2006 , 12, 2406-11	5.6	34
50	Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: is there still a role for these drugs?. <i>World Journal of Gastroenterology</i> , 2006 , 12, 5078-80	5.6	9
49	Insulin resistance as a non-invasive method for the assessment of fibrosis in patients with hepatitis C: a comparative study of biochemical methods. <i>Revista Espanola De Enfermedades Digestivas</i> , 2006 , 98, 161-9	0.9	5
48	Hepatitis C and insulin resistance: steatosis, fibrosis and non-response. <i>Revista Espanola De Enfermedades Digestivas</i> , 2006 , 98, 605-15	0.9	18
47	Results of a survey in Andalusian endoscopy units. <i>Revista Espanola De Enfermedades Digestivas</i> , 2006 , 98, 929-48	0.9	2
46	Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. <i>Gastroenterology</i> , 2005 , 129, 512-21	13.3	681
45	HLA-C and KIR genes in hepatitis C virus infection. <i>Human Immunology</i> , 2005 , 66, 1106-9	2.3	38
44	Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. <i>Gastroenterology</i> , 2005 , 128, 636-41	13.3	607

43	Insulin resistance and hepatitis C. <i>Gastroenterology</i> , 2005 , 128, 2178; author reply 2178-9	13.3	
42	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. <i>Gastroenterology</i> , 2005 , 129, 512-521	13.3	554
41	HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. <i>Hepatology</i> , 2005 , 41, 779-89	11.2	214
40	Role of phosphate-activated glutaminase in the pathogenesis of hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2005 , 20, 319-25	3.9	29
39	Serum immunological profile in patients with chronic autoimmune cholestasis. <i>American Journal of Gastroenterology</i> , 2004 , 99, 2150-7	0.7	17
38	Transient Budd-Chiari syndrome due to iatrogenic subcapsular fluid accumulation following thoracentesis. <i>American Journal of Gastroenterology</i> , 2004 , 99, 2281-2	0.7	
37	Histologic features of steatohepatitis in patients with a clinical diagnosis of autoimmune cholestasis. <i>Digestive Diseases and Sciences</i> , 2004 , 49, 1957-61	4	4
36	Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy. <i>Hepatology</i> , 2004 , 39, 939-43	11.2	50
35	HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. <i>Hepatology</i> , 2004 , 39, 1603-12	11.2	120
34	Hepatotoxicity induced by clopidogrel. <i>Journal of Hepatology</i> , 2004 , 40, 560-2	13.4	22
33	Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. <i>Journal of Hepatology</i> , 2004 , 41, 49-54	13.4	83
32	SLC11A1 promoter gene polymorphisms and fibrosis progression in chronic hepatitis C. <i>Gut</i> , 2004 , 53, 446-50	19.2	22
31	509 Sustained virological response after prolonged treatment with peginterferon alfa-2A (40KD) (PEGASYS [®]) and ribavirin (COPEGUS [®]) in treatment-naïve patients with chronic hepatitis C and detectable HCV RNA after week 4 of therapy: teravic-4 study. <i>Journal of Hepatology</i> , 2004 , 40, 150	13.4	6
30	Tumour necrosis factor alpha polymorphisms are not involved in the development of steatosis in chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2004 , 16, 761-5	2.2	6
29	Familial Mediterranean fever mimicking Fitz-Hugh-Curtis syndrome. <i>American Journal of Gastroenterology</i> , 2003 , 98, 701	0.7	2
28	Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2003 , 98, 1135-41	0.7	77
27	Macro-AST as cause of unknown hypertransaminasaemia. <i>European Journal of Gastroenterology and Hepatology</i> , 2003 , 15, 103-4	2.2	4
26	Three-day intravenous triple therapy is not effective for the eradication of <i>Helicobacter pylori</i> infection in patients with bleeding gastro-duodenal ulcer. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 18, 1023-9	6.1	2

25	Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2003 , 98, 1135-1141	0.7	17
24	HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2003 , 98, 1621-1626	0.7	4
23	HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2003 , 98, 1621-6	0.7	21
22	Lansoprazole-induced hepatic dysfunction. <i>Annals of Pharmacotherapy</i> , 2003 , 37, 1731	2.9	4
21	Fatigue is associated with high circulating leptin levels in chronic hepatitis C. <i>Gut</i> , 2003 , 52, 915	19.2	2
20	Fatigue is associated with high circulating leptin levels in chronic hepatitis C. <i>Gut</i> , 2002 , 51, 434-9	19.2	50
19	Infliximab induces remission of pyoderma gangrenosum. <i>European Journal of Gastroenterology and Hepatology</i> , 2002 , 14, 907	2.2	26
18	Anticoagulation therapy for recent portal vein thrombosis in a patient with liver cirrhosis suffering from variceal rebleeding. <i>Gastroenterology</i> , 2002 , 122, 2095	13.3	15
17	Altered response to oral glutamine challenge as prognostic factor for overt episodes in patients with minimal hepatic encephalopathy. <i>Journal of Hepatology</i> , 2002 , 37, 781-7	13.4	53
16	Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2718-23	0.7	284
15	Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. <i>American Journal of Gastroenterology</i> , 2001 , 96, 2718-2723	0.7	47
14	Hepatotoxicity induced by fosinopril. <i>Journal of Hepatology</i> , 2001 , 35, 309-10	13.4	7
13	Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption. <i>Digestive and Liver Disease</i> , 2001 , 33, 698-702	3.3	37
12	Antiphospholipid antibodies are related to portal vein thrombosis in patients with liver cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2000 , 31, 237-40	3	41
11	Acute hepatitis after starting zinc therapy in a patient with presymptomatic Wilson's disease. <i>Hepatology</i> , 2000 , 32, 877	11.2	8
10	Prevalencia y significado clínic de los anticuerpos antifosfolipídicos en la hepatitis crónica por virus C. <i>Medicina Clínica</i> , 2000 , 114, 367-370	1	5
9	HLA antigens in chronic hepatitis C: Relationship with interferon response and severity of liver injury. <i>Journal of Hepatology</i> , 2000 , 32, 129	13.4	91
8	Norfloxacin-induced acute cholestatic hepatitis in a patient with alcoholic liver cirrhosis. <i>American Journal of Gastroenterology</i> , 1999 , 94, 2324-5	0.7	13

7	Pancreatic abscess due to <i>Streptococcus salivarius</i> after dental manipulation. <i>American Journal of Gastroenterology</i> , 1999 , 94, 1987-8	0.7	2
6	Acute cholestatic hepatitis induced by nimesulide. <i>Liver International</i> , 1999 , 19, 164-5	7.9	14
5	Acute hepatitis related to omeprazole. <i>American Journal of Gastroenterology</i> , 1999 , 94, 1119-20	0.7	14
4	Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. <i>Journal of Hepatology</i> , 1999 , 31, 641-6	13.4	45
3	Pseudomembranous colitis induced by diclofenac. <i>Journal of Clinical Gastroenterology</i> , 1998 , 26, 228	3	36
2	Sarcoidosis, sclerosing cholangitis, and chronic atrophic autoimmune gastritis: a case of infiltrative sclerosing cholangitis. <i>Journal of Clinical Gastroenterology</i> , 1998 , 27, 162-5	3	13
1	A Sustainable Development Goal framework to guide multisectoral action on NAFLD through a societal approach		1